Entry |
|
Name |
Selenocompound metabolism
|
Class |
Metabolism; Metabolism of other amino acids
|
Pathway map |

|
Disease |
H01285 | Methylcobalamin deficiency type G |
|
Reference |
|
Authors |
Hoefig CS, Renko K, Kohrle J, Birringer M, Schomburg L |
Title |
Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. |
Journal |
|
Reference |
|
Authors |
McKenzie MJ, Hunter DA, Pathirana R, Watson LM, Joyce NI, Matich AJ, Rowan DD, Brummell DA |
Title |
Accumulation of an organic anticancer selenium compound in a transgenic Solanaceous species shows wider applicability of the selenocysteine methyltransferase transgene from selenium hyperaccumulators. |
Journal |
|
Reference |
|
Authors |
Pinto JT, Lee JI, Sinha R, MacEwan ME, Cooper AJ |
Title |
Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. |
Journal |
|
Reference |
|
Authors |
Suzuki KT, Kurasaki K, Suzuki N |
Title |
Selenocysteine beta-lyase and methylselenol demethylase in the metabolism of Se-methylated selenocompounds into selenide. |
Journal |
|
Reference |
|
Authors |
Gromer S, Gross JH |
Title |
Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase. Implications for the antitumor effects of selenium. |
Journal |
|
KO pathway |
|